MarketPeel
Insider Trading Intelligence
Pricing
…
MB

Matthias Bodenstedt

MLTX
CHIEF FINANCIAL OFFICER · MOONLAKE IMMUNOTHERAPEUTICS · CIK 0001920545
FILING MIX · LIFETIME29%/71%
BUYS
7
SELLS
17
TOTAL VALUE
$9.21M
COMPANIES
1
ACTIVE SINCE
Apr 2023
HOLDINGS NOW
1,115,435
AVG SELL PX
$34.94
TRADE KIND
SHOWING 24 / 24
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 19 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Matthias Bodenstedt, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+57.14%+0.49%+1.47%-0.97%-2.40%—
14d7+100.00%-4.15%+1.77%-6.09%-6.13%—
30d7+85.71%-1.74%+3.85%-5.59%-7.75%—
60d7(1 pending)+50.00%+9.49%+6.25%+3.24%-6.72%—
90d7(4 pending)+100.00%-2.67%+7.20%-9.87%-22.54%—
180d7(4 pending)+100.00%+7.89%+10.22%-2.33%-47.38%—
1y7(5 pending)+100.00%-11.16%+25.49%-36.65%-36.65%—
2y7(5 pending)+100.00%-77.26%+46.19%-123.45%-123.45%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
MLTX · 1,115,435 shares · as of Jun 22, 2026
0319,076638,153957,2291,276,305202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 7 buys / 17 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE10b5-1
10b5-1 plan
39,120$22.04$862.2K1,115,435Jun 22, 2026Jun 23, 2026 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE10b5-1
10b5-1 plan
2,794$19.60$54.8K1,154,555Jun 18, 2026Jun 18, 2026 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE10b5-1
10b5-1 plan
15,082$19.68$296.8K1,157,349Jun 17, 2026Jun 18, 2026 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE10b5-1
10b5-1 plan
13,653$20.02$273.3K1,172,431May 11, 2026May 13, 2026 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE10b5-1
10b5-1 plan
2,426$19.56$47.5K1,186,084Apr 14, 2026Apr 16, 2026 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE10b5-1
10b5-1 plan
1,925$19.51$37.6K1,188,510Apr 10, 2026Apr 10, 2026 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE10b5-1
10b5-1 plan
85,870$18.94$1.63M1,190,435Apr 9, 2026Apr 10, 2026 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASEGRANT
Stock grant
354,296——1,276,305Jan 7, 2026Jan 9, 2026 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASE
Chief Financial Officer
294,473——922,009Dec 19, 2025Dec 22, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
Chief Financial Officer
294,473——0Dec 19, 2025Dec 22, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
Chief Financial Officer
8,754——0Dec 19, 2025Dec 22, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASE
Chief Financial Officer
10,870$9.09$98.8K627,536Oct 8, 2025Oct 9, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASEGRANT
Stock grant
95,763——616,666Feb 27, 2025Mar 3, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE10b5-1
10b5-1 plan
5,264$58.34$307.1K520,903Dec 20, 2023Dec 21, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE10b5-1
10b5-1 plan
94,736$59.22$5.61M526,167Dec 19, 2023Dec 21, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASE
Chief Financial Officer
62,972——620,903Oct 1, 2023Oct 3, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
Chief Financial Officer
62,972——294,473Oct 1, 2023Oct 3, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
Chief Financial Officer
1,872——8,754Oct 1, 2023Oct 3, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
Chief Financial Officer
410,796——0Apr 5, 2023Apr 7, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
Chief Financial Officer
12,212——0Apr 5, 2023Apr 7, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
Chief Financial Officer
147,135——357,445Apr 5, 2023Apr 7, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
Chief Financial Officer
4,374——10,626Apr 5, 2023Apr 7, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASE
Chief Financial Officer
147,135——557,931Apr 5, 2023Apr 7, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASE
Chief Financial Officer
410,796——410,796Apr 5, 2023Apr 7, 2023 ↗View →
Other insiders · MLTX
Loading peer insiders…
About this filer
CIK 0001920545
ROLE
Chief Financial Officer
PRIMARY
MLTX
COMPANIES
1
ACTIVE SINCE
Apr 2023
MARKETPEEL · /INSIDER/0001920545DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback